(Q48305058)

10 February 2018

title

Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo. (English)

1 reference

10 February 2018

1 reference

H Akiko Popiel

1

1 reference

10 February 2018

Yoshitaka Nagai

series ordinal

2

1 reference

10 February 2018

Nobuhiro Fujikake

series ordinal

3

1 reference

10 February 2018

Tatsushi Toda

series ordinal

4

1 reference

10 February 2018

publication date

1 February 2007

1 reference

10 February 2018

published in

Molecular Therapy

1 reference

10 February 2018

volume

15

1 reference

10 February 2018

issue

2

1 reference

10 February 2018

page(s)

303-309

1 reference

10 February 2018

Toxic proteins in neurodegenerative disease

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Expansion explosion: new clues to the pathogenesis of repeat expansion neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Protein aggregation and neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Expanded polyglutamine domain proteins bind neurofilament and alter the neurofilament network.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Protein aggregation in Huntington's and Parkinson's disease: implications for therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Transduction peptides: from technology to physiology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Protein transduction technology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Protection against ischemic brain injury by protein therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Amino Acid Sequence Requirements of Peptides That Inhibit Polyglutamine-Protein Aggregation and Cell Death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Small G-protein Rho is involved in the maintenance of cardiac myocyte morphology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Opinion: What is the role of protein aggregation in neurodegeneration?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

A seed for Alzheimer amyloid in the brain.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300045

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300045

1 reference

10 February 2018

PubMed ID

17235308

1 reference

10 February 2018